Valeant Pharmaceuticals’ affiliate has entered into a definitive agreement to acquire Synergetics USA, Inc. in a transaction valued at $166 million, with additional sales milestones following the closing. The transaction, subject to customary closing conditions, is expected to close in 4Q15. Synergetics is a supplier of precision surgical devices with a primary focus on ophthalmology and neurosurgery.   “The addition of Synergetics’ portfolio of instruments and devices will further...